(window.webpackJsonp=window.webpackJsonp||[]).push([[133],{877:function(a,t,e){"use strict";e.r(t);var n=e(12),r=Object(n.a)({},(function(){var a=this,t=a.$createElement,e=a._self._c||t;return e("ContentSlotsDistributor",{attrs:{"slot-key":a.$parent.slotKey}},[e("h2",{attrs:{id:"耐药肺炎克雷伯菌-包括碳青霉烯耐药"}},[e("a",{staticClass:"header-anchor",attrs:{href:"#耐药肺炎克雷伯菌-包括碳青霉烯耐药"}},[a._v("#")]),a._v(" 耐药肺炎克雷伯菌（包括碳青霉烯耐药）")]),a._v(" "),e("h2",{attrs:{id:"crkp耐药机制"}},[e("a",{staticClass:"header-anchor",attrs:{href:"#crkp耐药机制"}},[a._v("#")]),a._v(" CRKP 耐药机制")]),a._v(" "),e("p",[a._v("========\nCRKP 耐药主要是因为该菌株产碳青霉烯酶。\n高效水解青霉素、头孢菌素、氨曲南和碳青霉烯类抗生素，其主要包括肺炎克雷伯杆菌碳青霉烯酶 (Klebsiella pneumoniaecarbapenemase，KPC)、新德里金属蛋白酶 (new Delhi metallo-β-lactamase，NDM)、VIM、苯唑西林酶 - 48 (Oxacillinase-48，OXA-48) 等。其中产 KPC 为 CRKP 耐药的主要原因。")]),a._v(" "),e("h2",{attrs:{id:"crkp抗感染"}},[e("a",{staticClass:"header-anchor",attrs:{href:"#crkp抗感染"}},[a._v("#")]),a._v(" CRKP 抗感染")]),a._v(" "),e("p",[a._v("=======")]),a._v(" "),e("ol",[e("li",[a._v("多黏菌素 B 与美罗培南或替加环素联合。")]),a._v(" "),e("li",[a._v("替加环素的二联、三联 (包括与美罗培南的联合)")]),a._v(" "),e("li",[a._v("替加环素联合氨基糖苷类、环丙沙星治疗")]),a._v(" "),e("li",[a._v("含阿维巴坦 β 内酰胺酶复合制剂（头孢他啶 - 阿维巴坦）。")]),a._v(" "),e("li",[a._v("磷霉素 + 替加环素")])]),a._v(" "),e("p",[a._v("我国产新德里金属酶 NDM 基因型细菌高发，头孢他啶 / 阿维巴坦不能覆盖，临床治疗需要注意。")]),a._v(" "),e("h2",{attrs:{id:"crkp抗生素治疗结局"}},[e("a",{staticClass:"header-anchor",attrs:{href:"#crkp抗生素治疗结局"}},[a._v("#")]),a._v(" CRKP 抗生素治疗结局")]),a._v(" "),e("p",[a._v("===========\n54 个研究，3195 例 CRKP 感染患者\n 1. 病死率 37.2%\n2. 临床有效 69%\n3. 微生物学有效 63.7%\n4. 单药治疗死亡率高于联合治疗（临床疗效和微生物学疗效无统计学差异）\n5. 两药联合与三药联合没有差异 (病死率、临床疗效和微生物学疗效无统计学差异）")]),a._v(" "),e("p",[a._v("Agyeman AA, Bergen PJ, Rao GG, Nation RL, Landersdorfer CB. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020 Jan;55(1):105833. doi: 10.1016/j.ijantimicag.2019.10.014. Epub 2019 Nov 12. PMID: 31730892.")]),a._v(" "),e("p",[a._v("10 向研究 481 例 CRKP 感染患者。\n1. 多粘菌素单药治疗病死率高于多粘菌素联合治疗 (BSI 和 VAP）。\n2. 亚组分析，多粘菌素单药治疗病死率高于多粘菌素与替加环素或碳青霉烯的联合治疗，但氨基糖甙类除外。\n3. 多粘菌素三药联合有明显生存获益。")])])}),[],!1,null,null,null);t.default=r.exports}}]);